Complete financial analysis of SCYNEXIS, Inc. (SCYX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of SCYNEXIS, Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- DUET Acquisition Corp. (DUETW) Income Statement Analysis – Financial Results
- RTCL Limited (RAGHUTOB.BO) Income Statement Analysis – Financial Results
- PT HATTEN BALI Tbk (WINE.JK) Income Statement Analysis – Financial Results
- Astro Communications, Inc. (ASTO) Income Statement Analysis – Financial Results
- Rural Funds Group (RFNDF) Income Statement Analysis – Financial Results
SCYNEXIS, Inc. (SCYX)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.scynexis.com
About SCYNEXIS, Inc.
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 140.14M | 5.09M | 13.16M | 0.00 | 121.00K | 257.00K | 257.00K | 257.00K | 257.00K | 1.26M | 16.86M | 16.84M |
| Cost of Revenue | 15.62M | 628.00K | 312.00K | 303.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 15.45M | 16.31M | 14.36M |
| Gross Profit | 124.52M | 4.46M | 12.85M | -303.00K | 121.00K | 257.00K | 257.00K | 257.00K | 257.00K | -14.19M | 552.00K | 2.47M |
| Gross Profit Ratio | 88.85% | 87.66% | 97.63% | 0.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | -1,129.78% | 3.27% | 14.69% |
| Research & Development | 30.93M | 27.26M | 23.77M | 36.52M | 38.39M | 21.56M | 18.33M | 20.08M | 16.44M | 8.29M | 4.36M | 8.93M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.68M | 8.25M | 8.00M | 12.17M | 7.57M | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 48.00K | 0.00 | 0.00 |
| SG&A | 20.92M | 62.96M | 49.92M | 14.63M | 10.65M | 8.68M | 8.25M | 8.00M | 12.17M | 7.62M | 4.38M | 4.74M |
| Other Expenses | 0.00 | 3.00K | -13.00K | -334.00K | 538.00K | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 4.38M | 12.00K |
| Operating Expenses | 51.85M | 90.22M | 73.68M | 50.82M | 49.04M | 30.24M | 26.58M | 28.07M | 28.61M | 15.90M | 8.74M | 13.67M |
| Cost & Expenses | 67.47M | 90.85M | 73.99M | 50.82M | 49.04M | 30.24M | 26.58M | 28.07M | 28.61M | 15.90M | 25.05M | 28.03M |
| Interest Income | 3.95M | 1.42M | 24.00K | 189.00K | 805.00K | 967.00K | 386.00K | 185.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3.13M | 5.20M | 2.66M | 1.18M | 986.00K | 2.05M | 1.86M | 351.00K | 11.00K | 803.00K | 11.89M | 972.00K |
| Depreciation & Amortization | 810.00K | 813.00K | 577.00K | 303.00K | 285.00K | 53.00K | 41.00K | 26.00K | 447.00K | 1.24M | 1.33M | 1.49M |
| EBITDA | 73.48M | -59.91M | -31.41M | -51.15M | -51.27M | -17.10M | -23.16M | -29.51M | -27.90M | -2.19M | -13.76M | -9.71M |
| EBITDA Ratio | 52.43% | -1,675.94% | -468.93% | 0.00% | -40,196.69% | -11,269.65% | -10,075.10% | -10,780.54% | -10,856.81% | -1,128.50% | -61.39% | -74.91% |
| Operating Income | 72.67M | -85.76M | -60.83M | -51.15M | -48.92M | -29.98M | -26.32M | -27.82M | -28.35M | -14.65M | -7.20M | -7.78M |
| Operating Income Ratio | 51.85% | -1,684.48% | -462.09% | 0.00% | -40,430.58% | -11,666.54% | -10,241.25% | -10,823.74% | -11,030.74% | -1,166.16% | -42.74% | -46.23% |
| Total Other Income/Expenses | -5.49M | 18.25M | 24.88M | -7.18M | -4.79M | 10.78M | 1.26M | -2.17M | 11.00K | 7.88M | -23.26M | -281.00K |
| Income Before Tax | 67.18M | -67.51M | -35.95M | -58.33M | -53.71M | -19.20M | -25.06M | -29.99M | -28.34M | -6.77M | -30.46M | -11.48M |
| Income Before Tax Ratio | 47.94% | -1,326.05% | -273.14% | 0.00% | -44,388.43% | -7,472.37% | -9,750.97% | -11,668.87% | -11,026.46% | -538.93% | -180.70% | -68.17% |
| Income Tax Expense | 138.00K | -4.70M | -3.09M | -3.15M | 1.52M | -6.74M | 1.86M | 351.00K | -4.29M | -1.17M | 11.89M | 984.00K |
| Net Income | 67.04M | -62.81M | -32.87M | -55.19M | -55.23M | -12.47M | -25.06M | -29.99M | -32.62M | -4.23M | -30.46M | -11.48M |
| Net Income Ratio | 47.84% | -1,233.73% | -249.68% | 0.00% | -45,647.93% | -4,851.36% | -9,750.97% | -11,668.87% | -12,693.77% | -337.10% | -180.70% | -68.17% |
| EPS | 1.40 | -1.47 | -1.25 | -5.15 | -9.85 | -2.84 | -9.37 | -15.75 | -26.82 | -7.48 | -192.64 | -72.58 |
| EPS Diluted | 1.39 | -1.47 | -1.25 | -5.15 | -9.85 | -2.84 | -9.37 | -15.75 | -26.82 | -7.13 | -192.64 | -72.58 |
| Weighted Avg Shares Out | 47.85M | 42.61M | 26.38M | 10.72M | 5.61M | 4.39M | 2.67M | 1.90M | 1.22M | 566.33K | 158.13K | 158.13K |
| Weighted Avg Shares Out (Dil) | 48.39M | 42.61M | 26.38M | 10.72M | 5.61M | 4.39M | 2.67M | 1.90M | 1.22M | 593.71K | 158.13K | 158.13K |
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
LOS ANGELES , Dec. 1, 2023 /PRNewswire/ -- Glancy Prongay & Murray LLP ("GPM") announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against SCYNEXIS, Inc. ("Scynexis" or the "Company") (NASDAQ: SCYX). Class...
IMPORTANT DEADLINE REMINDER: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / December 1, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX) for violations of §§10(b) and...
SCYNEXIS INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Scynexis To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Scynexis between March 31, 2023 and September 22, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also...
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 30, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX) for violations of 10(b) and...
IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 29, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX) for violations of 10(b) and...
SCYX Investors Have Opportunity to Lead SCYNEXIS, Inc. Securities Fraud Lawsuit
LOS ANGELES , Nov. 29, 2023 /PRNewswire/ -- The Law Offices of Frank R. Cruz announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against SCYNEXIS, Inc. ("Scynexis" or the "Company") (NASDAQ: SCYX).
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SCYNEXIS, Inc. - SCYX
NEW YORK , Nov. 28, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of SCYNEXIS, Inc. ("SCYNEXIS" or the "Company") (NASDAQ: SCYX). Such investors are advised to contact Robert S.
DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 27, 2023 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX) for violations of 10(b) and...
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in SCYNEXIS, Inc. with Losses of $100,000 to Contact the Firm
LOS ANGELES, CA / ACCESSWIRE / November 27, 2023 / The Schall Law Firm,, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against SCYNEXIS, Inc. ("SCYNEXIS" or "the Company") (NASDAQ:SCYX) for violations of 10(b) and...
ROSEN, A TOP RANKED LAW FIRM, Encourages SCYNEXIS, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SCYX
NEW YORK , Nov. 26, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of SCYNEXIS, Inc. (NASDAQ: SCYX) between March 31, 2023 and September 22, 2023, both dates inclusive (the "Class...
Source: https://incomestatements.info
Category: Stock Reports